TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Rashmi Kanagal-ShamanaPreetesh JainKoichi TakahashiNicholas James ShortGuilin TangGhayas C IssaFarhad RavandiGuillermo Garcia-ManeroCameron C YinRajyalakshmi LuthraKeyur P PatelJoseph D KhouryGuillermo Montalban-BravoKoiji SasakiTapan Mahendra KadiaGautam BorthakurMarina KonoplevaNitin JainRebecca GarrisSherry PierceWilliam WierdaZeev EstrovJorge CortesSusan M O'BrienHagop M KantarjianElias JabbourPublished in: Cancer (2017)
Hyper-CVAD-based regimens appear to negate the poor prognostic impact of TP53 mutations in patients with adult B-cell immunophenotype ALL. Cancer 2017;123:3717-24. © 2017 American Cancer Society.